Home » Archive

Marketwire, News, NYSE:PFE, Syndication »

Lpath Granted Two Additional U.S. Patents Related to iSONEP and ASONEP Drug Programs

Posted by Mary Canady October 5th, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Oct 5, 2011) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that Lpath has been issued two fur…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Granted Two Additional U.S. Patents Related to iSONEP and ASONEP Drug Programs

Posted by Mary Canady October 5th, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Oct 5, 2011) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that Lpath has been issued two fur…

More...

Marketwire, News, Syndication »

Quidel to Hold Third Quarter 2011 Financial Results Conference Call on October 25, 2011

Posted by Mary Canady October 4th, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Oct 4, 2011) – Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, will release third quarter 2011 financial results after market close on Tuesd…

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Initiates Dosing of iSONEP in First of Two Proof-of-Concept Trials

Posted by Mary Canady September 29th, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Sep 29, 2011) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has initiated dosing in its PEDigree clinical trial where iSONEPT is being investigated as a treatment for retinal …

More...

Uncategorized »

Lpath Initiates Dosing of iSONEP in First of Two Proof-of-Concept Trials

Posted by Mary Canady September 29th, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Sep 29, 2011) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has initiated dosing in its PEDigree clinical trial where iSONEPT is being investigated as a treatment for retinal …

More...

Marketwire, News, Syndication »

Medistem to Discuss Immunological Aspects of Endometrial Regenerative Cells at Providence Multiple Sclerosis Center

Posted by Mary Canady September 28th, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Sep 28, 2011) – Medistem Inc. (PINKSHEETS: MEDS) announced today that its Chief Executive Officer, Thomas Ichim, will be giving an academic lecture at the Providence Multiple Sclerosis Center, in Portland, Oregon on Sept …

More...

Uncategorized »

Cytori & Apollo Hospitals Group of India Formalize Celution(R) Agreement

Posted by Mary Canady September 23rd, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Sep 23, 2011) – Cytori Therapeutics (NASDAQ: CYTX) has entered into a Celution┬« System agreement with Apollo Hospitals, one of Asia’s largest private healthcare groups, to offer the technology initially at select cosmet…

More...

Marketwire, News, Syndication »

Cytori & Apollo Hospitals Group of India Formalize Celution(R) Agreement

Posted by Mary Canady September 23rd, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Sep 23, 2011) – Cytori Therapeutics (NASDAQ: CYTX) has entered into a Celution┬« System agreement with Apollo Hospitals, one of Asia’s largest private healthcare groups, to offer the technology initially at select cosmet…

More...

Marketwire, News, Syndication »

Cytori & Apollo Hospitals Group of India Formalize Celution(R) Agreement

Posted by Mary Canady September 23rd, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Sep 23, 2011) – Cytori Therapeutics (NASDAQ: CYTX) has entered into a Celution┬« System agreement with Apollo Hospitals, one of Asia’s largest private healthcare groups, to offer the technology initially at select cosmet…

More...

Uncategorized »

Medistem Receives FDA Approval to Begin Clinical Trial in USA With ERC Stem Cells

Posted by Mary Canady September 22nd, 2011 .
No Comments

SAN DIEGO, CA–(Marketwire – Sep 22, 2011) – Medistem Inc. (PINKSHEETS: MEDS) announced today approval from the FDA to initiate a dose-escalating clinical trial in patients with critical limb ischemia using its Endometrial Regenerative Cell (ERC) st…

More...